New Delhi, April 2 -- Emcure Pharmaceuticals on Thursday announced that it has halved the price of its weight management drug Poviztra, a semaglutide injection, in a move aimed at making obesity treatment more affordable for patients.

The company said the starting dose of Poviztra will now be priced at Rs.3,999 per month, down from Rs.8,790 earlier. Meanwhile, prices across higher doses have been reduced by an average of 47%.

The revised rates will come into effect from 3 April 2026, the company said.

The announcement comes just weeks after semaglutide, the molecule behind Danish drugmaker Novo Nordisk's blockbuster weight-loss drugs such as Ozempic and Wegovy, lost its patent protection in India.

This triggered a wave of launches by ...